Are low-cost generic drugs a thing of the past?
BioPharma Dive - December 3, 2014
The reality that generic drug prices have risen dramatically is no longer news. Since July, stories about skyrocketing generic drug prices have proliferated, including multiple examples of drug costs that have been hiked to a staggering, and even unbelieable, degree.
New statin guidelines suggest that most patients between 60 and 75 years old should use statins to maintain their heart health
dailyRx News - November 24, 2014
When it comes to deciding which patients should take statins to keep their hearts healthy, the focus may be shifting. Recent guidelines on statin use focused less on cholesterol levels and more on other factors, such as age or a history of diabetes.
Moody's outlook on non-profit sector remains dim
Healthcare Dive - December 3, 2014
Moody's Investors Service has retained its negative outlook on not-for-profit hospitals in 2015, predicting that operating margins will continue to weaken.
Why patients respond to a life-saving melanoma drug
ScienceDaily - November 26, 2014
Researchers have pioneered a new methodology to predict why some patients battling advanced melanoma respond well or not at all to the new breakthrough drug pembrolizumab (Keytruda).
IMS: Rebates, discounts could take an $80B bite out of U.S. drug spending through 2018
FiercePharmaMarketing - December 3, 2014
U.S. spending growth on medicines is headed for a peak this year, IMS' annual spending report says. But as payers put the squeeze on drugmakers to put their best deal forward, that doesn't mean rebates and discounts won't be taking their toll on sales.
Hypertensive Patients Tested Infrequently for Diabetes
Pharmacy Times - November 30, 2014
Although hypertension and diabetes are often comorbid conditions, nearly one-third of hypertensive patients have not had their blood sugar tested in the last 3 years, according to research published online in Preventing Chronic Disease on November 26, 2014.
Roche's Genentech defends supply shift for top cancer drugs
Reuters - November 24, 2014
Genentech, U.S. biotech unit of Roche Holding, faces growing pressure over a decision to allow only a handful of distributors to supply three of the world's most widely used cancer drugs, a move that prominent hospitals say will create delays and raise costs.
CDC: Only 30% of Americans with HIV have the virus under control
Drug Store News - November 26, 2014
Just 30% of Americans with HIV had the virus under control in 2011, and approximately two-thirds of those whose virus was out of control had been diagnosed but were no longer in care, according to a new Vital Signs report published Tuesday by the Centers for Disease Control and Prevention.
U.S. designates 35 hospitals as Ebola treatment centers
Reuters - December 2, 2014
U.S. health officials have designated 35 hospitals nationwide as Ebola treatment centers and expects to name more in coming weeks deemed capable of treating patients while minimizing risk to staff, the U.S. Centers for Disease Control and Prevention said on Tuesday.
A $945 million breakup: J&J, Astellas call off major rheumatoid arthritis deal
BioPharma Dive - December 3, 2014
In 2012, Johnson & Johnson and Astellas entered a partnership deal in which J&J paid $65 million up front to Astellas for acqusition rights to ASP015K, an oral JAK inhibitor intended for treatment of rheumatoid arthritis (RA).
Statins Won't Help Protect Bones, Study Finds
HealthDay News - December 1, 2014
The cholesterol-lowering drugs known as statins have been touted by some as capable of reducing the risk for broken bones. But, it appears that's not the case, a new study finds.
Contact,
Jan Tankersley
Senior Vice President, Marketing & Sales
Pharmaceutical Strategies Group (PSG)
Office: 972-943-7141
Email: JTankersley@PSGConsults.com
PSGNewsletter@PSGConsults.com
www.PSGConsults.com
 |
 |
 |